SlideShare a Scribd company logo
Investigating and
Prosecuting Pill Mills
Presenters:
•Jennifer Doll, Special Agent, California Department of Justice
•John Niedermann, JD, Deputy District Attorney, Los Angeles
County District Attorney’s Office
Pre-Summit Workshop
Moderator: Karen L. Kelly, District Director, Congressman Harold
“Hal” Rogers (KY-5th District), and Member, Rx and Heroin Summit
National Advisory Board
Disclosures
Jennifer Doll; John Niedermann, JD; and Karen L.
Kelly have disclosed no relevant, real, or
apparent personal or professional financial
relationships with proprietary entities that
produce healthcare goods and services.
Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following
to disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
Learning Objectives
1. Identify challenges and strategies related to
investigating a provider Rx drug case.
2. Distinguish the possible charges that could
be filed.
3. Explain how to prepare for and prosecute a
criminal trial against a medical professional.
PROSECUTING A PRESCRIPTION DRUG
CASE:
FROM COMPLAINT TO CONVICTION
--How investigations are initiated
-Constructing an investigation plan
-Identifying Drugs
-Conducting the investigation
-Collecting evidence
-Putting it all together
-Prosecution and legal issues
Course Overview:Course Overview:
PEOPLE V. TSENGPEOPLE V. TSENG (LESS THAN 3 YEARS)(LESS THAN 3 YEARS)
PC 187
PC 187
PC 187
PC 187
PC 187
PC 187
CONSUMER COMPLAINTCONSUMER COMPLAINT
-Patient
-Family member
-Another physician
-Pharmacist
INITIATION OFINITIATION OF
INVESTIGATIONINVESTIGATION
SPECIAL AGENT ROBERT HARKINS
BEGAN INVESTIGATION IN SEPTEMBER OFBEGAN INVESTIGATION IN SEPTEMBER OF
2008:2008:
TIPPED OFF BY LOCAL PHARMACISTSTIPPED OFF BY LOCAL PHARMACISTS
CONDUCTED SURVEILLANCE ON THE CLINICCONDUCTED SURVEILLANCE ON THE CLINIC
REVEALED LINES OF YOUNG PEOPLEREVEALED LINES OF YOUNG PEOPLE
SET UP A SERIES OF UNDERCOVERSET UP A SERIES OF UNDERCOVER
OPERATIONSOPERATIONS
INITIATION OFINITIATION OF
INVESTIGATIONINVESTIGATION
DEATH OF A PATIENTDEATH OF A PATIENT
--Report from a coroner (802.5)Report from a coroner (802.5)
-Family member reports death-Family member reports death
-Law enforcement-Law enforcement
RYAN LATHAMRYAN LATHAM
KELLY RALPHKELLY RALPH::
Had back pain with unknown source but appearedHad back pain with unknown source but appeared
to be a sports injury.to be a sports injury.
Thought 5 hydrocodone per day was safe.Thought 5 hydrocodone per day was safe.
DECEASED
DECEASED
INITIATION OFINITIATION OF
INVESTIGATIONINVESTIGATION
PDMPPDMP
CRIMINAL VERSUS ADMINSTRATIVE ACTIONSCRIMINAL VERSUS ADMINSTRATIVE ACTIONS
Over Prescribing
Fraudulent Prescribing
Money Laundering / Structuring
Tax Fraud
Insurance Fraud
Prescribing Without a Legitimate Medical Purpose
Prescribing to Addicts
Homicide
Sales/Distribution of Controlled Substances
Unlicensed Practice of Medicine
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Pros and Cons of Requesting Medical Records via
Written request, SDT or Search Warrant
THE SEARCH WARRANTS
2010 2012
SOME PATIENTS HAD BLANK
RECORDS IN 2010 THEN HAD
COMPLETED RECORDS IN 2012STEVEN OGLESTEVEN OGLE
2010 2012
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
PHARMACY RECORDS
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
IMPORTANTIMPORTANT to obtain original prescriptions early in an
investigation to avoid the destruction of the prescriptions and
loss of evidence.
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
A pharmacist should act as a second screener and is obligated
to verify prescriptions in which the legitimacy is questioned.
A pharmacist has obligations to go over proper usage of
medications in the form of “patient consultations.”
PHARMACISTSPHARMACISTS
ALFONSO VERCUEIL ANGELA LI LYDIA BRAY KIMBERLY QUACH
• YOUNG WHITE MALESYOUNG WHITE MALES
• PAYING LARGE AMOUNTS OF CASHPAYING LARGE AMOUNTS OF CASH
• ASKING FOR BRAND NAMESASKING FOR BRAND NAMES
• APPEARING HEALTHYAPPEARING HEALTHY
• REQUESTING UNUSUAL COMBINATIONS OF DRUGSREQUESTING UNUSUAL COMBINATIONS OF DRUGS
• SOME APPEARED UNDER THE INFLUENCESOME APPEARED UNDER THE INFLUENCE
• SOME APPEARED ANXIOUS OR AGITATEDSOME APPEARED ANXIOUS OR AGITATED
ANGELA LIANGELA LI: THE NUMBER OF PRESCRIPTIONS DID NOT DROP: THE NUMBER OF PRESCRIPTIONS DID NOT DROP
EVEN AS SHE WAS REFUSING THEMEVEN AS SHE WAS REFUSING THEM
LYDIA BRAYLYDIA BRAY: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES
AND STRENGTH LIKE THIS AND HASN’T SINCEAND STRENGTH LIKE THIS AND HASN’T SINCE
AUTOPSY REPORTS
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
TOXICOLOGY REPORTSTOXICOLOGY REPORTS
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Toxicology results are often provided with an autopsy report.
Typically, a 1 page summary report is provided with the end results
of the tests.
Be cautious of who signs the toxicology report, as MULTIPLE
toxicologists most likely ran tests and may not have signed the
report.
TOXICOLOGY
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Find out the lab’s retention policies and request that the
samples for your case be held longer if necessary.
Get information of chain of custody. Whose hands touched
the vial?? TOXICOLOGY
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Understanding the results…
Positive / negative versus quantitative
Contributing factor of death versus
substantial factor
Therapeutic versus non-therapeutic
TOXICOLOGY
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Metabolites- what are the metabolites of certain
prescription drugs
Metabolism – half life of a drug
TOXICOLOGY
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Dealing with multiple contributing factors from multiple sources
TOXICOLOGY
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Witnesses
How do I identify witnesses?
PDMP reports
Surveillance
Interviews
Pharmacy records
Complainant
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Witnesses: The Interview
How did the patient hear about the subject?
Did the patient have a legitimate medical condition?
How far did the patient travel to the clinic?
How did they pay? Cash? Insurance?
How long did they wait to see the subject versus length of exam?
Did the subject recommend a specific pharmacy?
Did the patient reveal a history of addiction to the subject? When?
Show the patient a 6-pack and ask that they identify the subject
Did they consume the pills? Sell?
INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Be sensitive to their needs / fears /
hesitations
Don’t judge their addiction or behaviors to
obtain medication
Talk to your prosecutor about witness
concerns and discuss immunity (case by
case basis)
Witnesses
“Holy TrinityHoly Trinity” – combination of three
drugs (Soma, Xanax, Vicodin) which
create a euphoria like heroin
IDENTIFYING DRUGSIDENTIFYING DRUGS
Addiction CertificateAddiction Certificate
Methadone prescribed for addiction requires a special
certificate issued through the DEA
(Methadone prescribed for pain does not require this
certificate, however the use of the medication must be
documented in the chart)
IDENTIFYING DRUGSIDENTIFYING DRUGS
IDENTIFYING DRUGSIDENTIFYING DRUGS
Identify Drugs in your Investigation Report
Include a brief summary identifying
drugs in your case
Include brand name, generic name and
schedule
Note for what condition drug is used
Cite current schedule at the time the
drug was dispensed or administered
THE UNDERCOVER OPERATIONS
SPECIAL AGENT STEPHANIE MORELANDSPECIAL AGENT STEPHANIE MORELAND APRIL 25, 2008APRIL 25, 2008
• TOLD DEFENDANT SHE NEEDED SOMETHING FOR CRAMPS
AND A HEADACHE
• TOLD THE DEFENDANT SHE WAS COMING FROM
OCEANSIDE
• NO PHYSICAL EXAM WAS GIVEN
• DEFENDANT SAID SHE WOULD PRESCRIBE VICODIN TO
TAKE THE EDGES OFF
UNCHARGEDUNCHARGED
Pain vs No pain
Recording Devices (should you have them? Where
should you put them?)
How many buys are necessary?
Establishing a rapport the doctor
Testifying after your U/C
Entrapment / Red flags
Undercover Investigations: IssuesUndercover Investigations: Issues
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
THE “MEATY” STUFFTHE “MEATY” STUFF
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
SEARCH WARRANTSSEARCH WARRANTS
What are you trying to obtain?
What probable cause is needed to obtain those
items?
Do you have probable cause?
Can you ever have too much information in a SW?
Tools to assist with SW writing
PREPARING SEARCH WARRANTSPREPARING SEARCH WARRANTS
SEARCH WARRANTSEARCH WARRANT
LOCATIONSLOCATIONS
HOMEHOME
BUSINESSBUSINESS
STORAGESTORAGE
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
SEARCH WARRANTSSEARCH WARRANTS
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
SEARCH WARRANTSSEARCH WARRANTS
Getting your warrant signed
- Finding a judge
- Educating your judge
- Know your case (the judge will probably ask questions)
EXECUTING
THE
WARRANT
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
EXECUTING A WARRANT
Securing the evidence:
If computer equipment is expected to be
taken, consider staff / subject destroying
evidence upon entry.
Do you have a technical team that can safely
remove digital data without compromising
the data?
COMPUTER RECORDSCOMPUTER RECORDS
COLLECTING EVIDENCECOLLECTING EVIDENCE
Specific language in SW to search computer files
Agency assist in collection of files
Agency assist in analyzing data- DOJ, FBI, locals,
etc.
Consider turn around time for data to be recovered
Search warrant return – language for additional
time for digital data
Consider the cloud
LUIS SALAZARLUIS SALAZAR
NO DAMAGE TONO DAMAGE TO
THE COMPUTERSTHE COMPUTERS
KNOW YOUR TARGETSKNOW YOUR TARGETS
WHO WAS THEREWHO WAS THERE
PHYSICIANPHYSICIAN WAS THE DOCTOR WITH AWAS THE DOCTOR WITH A
PATIENTPATIENT
WAS THE DOCTORWAS THE DOCTOR
COOPERATIVECOOPERATIVE
DID THE DOCTOR SUBMIT TODID THE DOCTOR SUBMIT TO
BE INTERVIEWEDBE INTERVIEWED
DOES THE DOCTOR HAVE ADOES THE DOCTOR HAVE A
PRIOR RECORDPRIOR RECORD
WHAT WAS THEIR CHIEF AREAWHAT WAS THEIR CHIEF AREA
OF PRACTICEOF PRACTICE
WHAT BOARDWHAT BOARD
CERTIFICATIONS DO THEYCERTIFICATIONS DO THEY
HAVEHAVE
WHO WAS THEREWHO WAS THERE
PHYSICIAN’S ASSISTANTPHYSICIAN’S ASSISTANT
WAS HE SEEING PATIENTSWAS HE SEEING PATIENTS
WHAT DUTIES WEREWHAT DUTIES WERE
DELEGATED TO HIMDELEGATED TO HIM
IS THERE A DELEGATION OFIS THERE A DELEGATION OF
SERVICES AGREEMENTSERVICES AGREEMENT
WHAT IS HIS SKILL SETWHAT IS HIS SKILL SET
WHAT HOURS DOES HE WORK INWHAT HOURS DOES HE WORK IN
RELATION TO THE DOCTORRELATION TO THE DOCTOR
WHO WAS THEREWHO WAS THERE
MEDICAL ASSISTANTMEDICAL ASSISTANT
RECEPTIONISTRECEPTIONIST
WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES
DO THEY HAVE MEDICALDO THEY HAVE MEDICAL
TRAININGTRAINING
HOW DO THEY INTERACT WITHHOW DO THEY INTERACT WITH
PATIENTSPATIENTS
WHO DOES BOOKKEEPINGWHO DOES BOOKKEEPING
HOW ARE RECORDS KEPTHOW ARE RECORDS KEPT
HOW DOES THE FRONT OF THEHOW DOES THE FRONT OF THE
OFFICE RUNOFFICE RUN
WHAT TYPES OF PATIENTS AREWHAT TYPES OF PATIENTS ARE
SEENSEEN
WHO WAS THEREWHO WAS THERE
RUNNERSRUNNERS
CAPPERSCAPPERS
WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES
HOW WERE THEY TRAINEDHOW WERE THEY TRAINED
HOW ARE THEY PAIDHOW ARE THEY PAID
WHAT IS THEIR RELATIONSHIP TOWHAT IS THEIR RELATIONSHIP TO
THE DOCTORTHE DOCTOR
PHYSICIAN’S OFFICE –Photos, Photos,
Photos
COLLECTING EVIDENCECOLLECTING EVIDENCE
STORAGE ROOM
HALLWAY
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
TODAYTODAY
THE FUTURETHE FUTURE
FINANCIAL RECORDSFINANCIAL RECORDS
COLLECTING EVIDENCECOLLECTING EVIDENCE
BANK RECORDSBANK RECORDS
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
ITEMS ESTABLISHING DOMINION AND CONTROL OF PREMISESITEMS ESTABLISHING DOMINION AND CONTROL OF PREMISES
(utility bills, leases, etc.)
SPECIFIC MEDICALSPECIFIC MEDICAL
RECORDS LISTED BYRECORDS LISTED BY
PATIENTPATIENT
Include a description of
what a medical record is.
(i.e. physical / electronic
charts, x-rays, phone
messages, insurance
billing, labs,
prescriptions, etc)
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
MEDICAL CHARTMEDICAL CHART BILLING STATEMENTBILLING STATEMENT
PHENTERMINEPHENTERMINE
COLLECTING EVIDENCECOLLECTING EVIDENCE
CELL PHONE INFORMATION VIA SEARCH WARRANTCELL PHONE INFORMATION VIA SEARCH WARRANT
WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A DRAWER:IN A DRAWER:
WAS IT CLOSED (KNOWLEDGE)WAS IT CLOSED (KNOWLEDGE)
WAS IT LOCKED (ACCESS)WAS IT LOCKED (ACCESS)
IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL)IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL)
WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)
WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
ON A SHELF:ON A SHELF:
HOW WERE THE RECORDS ARRANGED (STANDARD OFHOW WERE THE RECORDS ARRANGED (STANDARD OF
CARE)CARE)
WHO WAS RESPONSIBLE FOR MAKING NOTATIONSWHO WAS RESPONSIBLE FOR MAKING NOTATIONS
(KNOWLEDGE)(KNOWLEDGE)
WHO HAD ACCESS TO THE RECORDS (DELEGATION)WHO HAD ACCESS TO THE RECORDS (DELEGATION)
WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A BATHROOM:IN A BATHROOM:
WHO HAD ACCESS (STANDARD OF CARE)WHO HAD ACCESS (STANDARD OF CARE)
WERE CONTROLLED SUBSTANCES MIXED WITH NON-WERE CONTROLLED SUBSTANCES MIXED WITH NON-
CONTROLLED SUBSTANCES (NEGLIGENCE)CONTROLLED SUBSTANCES (NEGLIGENCE)
WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A PILL ROOM:IN A PILL ROOM:
WERE THERE LOOSE PILLS (NEGLIGENCE)WERE THERE LOOSE PILLS (NEGLIGENCE)
WERE THERE NON-MEDICAL ITEMS LOCATEDWERE THERE NON-MEDICAL ITEMS LOCATED
(STANDARD OF CARE)(STANDARD OF CARE)
WHO HAD ACCESS TO THE ROOM (CONTROL)WHO HAD ACCESS TO THE ROOM (CONTROL)
WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A CAR:IN A CAR:
WERE ITEMS LOCKED AND SECURED (STANDARD OFWERE ITEMS LOCKED AND SECURED (STANDARD OF
CARE)CARE)
WERE ITEMS LABELED OR SCRIPTS FILLED OUTWERE ITEMS LABELED OR SCRIPTS FILLED OUT
(MOTIVE)(MOTIVE)
COLLECTING EVIDENCECOLLECTING EVIDENCE
UNCONVENTIONALUNCONVENTIONAL
EVIDENCEEVIDENCE
PHARMACYPHARMACY
SIGNATURE LOGSSIGNATURE LOGS
COLLECTING EVIDENCECOLLECTING EVIDENCE
APPLICATIONS FOR CERTIFICATIONAPPLICATIONS FOR CERTIFICATION
COLLECTING EVIDENCECOLLECTING EVIDENCE
DIVERTED MEDICATION BOTTLESDIVERTED MEDICATION BOTTLES
COLLECTING EVIDENCECOLLECTING EVIDENCE
PHARMACIST
STEVE
MAZLIN
INTERVIEWS WITH PHARMICISTS:INTERVIEWS WITH PHARMICISTS:
WARNINGSWARNINGS
Chloral Hydrate is a veryChloral Hydrate is a very
powerful respiratorypowerful respiratory
suppressant. You don’t wantsuppressant. You don’t want
to end up on the cover of theto end up on the cover of the
“National Inquirer.”“National Inquirer.”
I had to correct Dr. Eroshevich onI had to correct Dr. Eroshevich on
the dosing on her prescription.the dosing on her prescription.
COLLECTING EVIDENCECOLLECTING EVIDENCE
HARD COPY PRESCRIPTIONSHARD COPY PRESCRIPTIONS
COLLECTING EVIDENCECOLLECTING EVIDENCE
ANNA NICOLE SMITH’S MEDICAL HISTORYANNA NICOLE SMITH’S MEDICAL HISTORY HOWARD K. STERN’S MEDICAL HISTORYHOWARD K. STERN’S MEDICAL HISTORY
INTAKE PATIENT PROFILESINTAKE PATIENT PROFILES
COLLECTING EVIDENCECOLLECTING EVIDENCE
EMAILSEMAILS
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
SURVEILLANCE VIDEO OR STILLSSURVEILLANCE VIDEO OR STILLS
COLLECTING EVIDENCECOLLECTING EVIDENCE
PERSONAL PHOTOGRAPHS: CORROBORATIONPERSONAL PHOTOGRAPHS: CORROBORATION
MAKE: CANON MODEL: CANON EOS DIGITALREBEL XT DATE: 2006:09:21 TIME: 02:13:36
COLLECTING EVIDENCECOLLECTING EVIDENCE
12/19/0612/19/06
EXTERNALEXTERNAL
HARD DRIVEHARD DRIVE
PERSONAL PHOTOGRAPHS: MOTIVEPERSONAL PHOTOGRAPHS: MOTIVE
COLLECTING EVIDENCECOLLECTING EVIDENCE
LOCATIONS WHERE PATIENTS LIVELOCATIONS WHERE PATIENTS LIVE
DOCTOR’S OFFICE
PATIENT RESIDENCES
30 MILES
COLLECTING EVIDENCECOLLECTING EVIDENCE
LANA RAULANA RAU
20072007
20082008
20092009
PATTERNS OF PRESCRIBINGPATTERNS OF PRESCRIBING
COLLECTING EVIDENCECOLLECTING EVIDENCE
Coroner’s Reports
Witness / family statements made to coroner investigators
Admissions of doctor to coroner staff / investigators
Coroner investigator notes (not included in autopsy report)
Photos:
COLLECTING EVIDENCECOLLECTING EVIDENCE
CORONER’S RECORDS
AND NOTES
COLLECTING EVIDENCECOLLECTING EVIDENCE
PILL COUNTS
COLLECTING EVIDENCECOLLECTING EVIDENCE
COLLECTING EVIDENCECOLLECTING EVIDENCE
EXPERT
REVIEW AND
OPINION
COLLECTING EVIDENCECOLLECTING EVIDENCE
EXPERT OPINIONS
Once evidence is obtained, determine if an
expert opinion is necessary.
Make sure the expert has the entire picture of
the case, not just a snap shot (for example, just
having an expert review a PDMP report)
COLLECTING EVIDENCECOLLECTING EVIDENCE
EXPERT OPINIONS
Expert opinions are critical to most over-prescribing cases.
Consider the strength of your case depending on your
expert’s findings: no departure, simple departure, extremeno departure, simple departure, extreme
departure and lack of knowledgedeparture and lack of knowledge
DR. WALTER STRAUSERDR. WALTER STRAUSER
THE STANDARD OF CARETHE STANDARD OF CARE
“THE LEVEL OF SKILL, KNOWLEDGE AND
CARE IN DIAGNOSING AND TREATING
THAT A REASONABLY PRUDENT
PHYSICIAN WOULD EXERCISE IN SIMILAR
CIRCUMSTANCES.”
THE SAME STANDARD OF CARE APPLIES TO ALL
PHYSICIANS
AN EXTREME DEPARTURE FROM THE STANDARD OF
CARE:
GROSS NEGLIGENCE AND LACK OF SCANT CARE
No inquiry into who the other doctors were
and why so much medication at his age
MEDICAL OPINIONSMEDICAL OPINIONS
EXTREME DEPARTUREEXTREME DEPARTURE
COLLECTING EVIDENCECOLLECTING EVIDENCE
TOXICOLOGISTTOXICOLOGIST
TOXICOLOGIST
TOXICOLOGIST “The Opana was 3-4 X
therapeutic levels and the main
contributor. Xanax was at
therapeutic levels. Opana was
the substantial cause of death.”
COLLECTING EVIDENCECOLLECTING EVIDENCE
FELONY MURDERFELONY MURDER
+TheThe unlawful killingunlawful killing of a human being,of a human being,
+WhetherWhether intentionalintentional,, unintentionalunintentional, or, or
accidentalaccidental,,
+WhichWhich occurs duringoccurs during the commissionthe commission
or attempted commission of a felony,or attempted commission of a felony,
+When the perpetrator had theWhen the perpetrator had the specificspecific
intentintent toto commit that specified felonycommit that specified felony
= MURDER
FELONY MURDERFELONY MURDER
+TheThe unlawful killingunlawful killing of a human being,of a human being,
+WhetherWhether intentionalintentional,, unintentionalunintentional, or, or
accidentalaccidental,,
+WhichWhich occurs duringoccurs during the commissionthe commission
or attempted commission of felony,or attempted commission of felony,
+When the perpetrator had theWhen the perpetrator had the specificspecific
intentintent toto commit that specified felonycommit that specified felony
= MURDER
CALIFORNIACALIFORNIA
OVER-PRESCRIBING STATUTESOVER-PRESCRIBING STATUTES
INTENTINTENT
22ndnd
DEGREE MURDERDEGREE MURDER
SECOND DEGREE MURDER
DANGEROUS TO LIFE
1. The killing resulted from an intentional act,
2. The natural consequences of the act are
dangerous to human life, and
3. The act was deliberately performed with
knowledge of the danger to, and with conscious
disregard for, human life.
• When the killing is the direct result of such an act, it isWhen the killing is the direct result of such an act, it is
not necessary to prove that the defendant intended thatnot necessary to prove that the defendant intended that
the act would result in the death of a human being.the act would result in the death of a human being.
EXPRESSMALICE
IMPLIEDMALICE
IINTENDTOKILLSOMEONE
IINTENDTODOSOMETHING
THATIKNOW
CANKILLSOMEONE
ANDIDON’TCARE
MURDERMURDER MURDERMURDER
-------------------------
-------------------------
20072007 20082008
20092009
20102010
STAVRONSTAVRON
DEATHDEATH
LATHAMLATHAM
DEATHDEATH
COOKCOOK
OVERDOSEOVERDOSE
KENNEYKENNEY
DEATHDEATH
NGUYENNGUYEN
DEATHDEATH
OGLEOGLE
DEATHDEATH
KATSNELSONKATSNELSON
DEATHDEATH
CHAMBERSCHAMBERS
DEATHDEATH
GOMEZGOMEZ
DEATHDEATH
HUGGARDHUGGARD
DEATHDEATHROVEROROVERO
DEATHDEATHBENDERBENDER
DEATHDEATHMATAMATA
DEATHDEATH
TIMELINETIMELINE APPRECIATIONAPPRECIATION
OF THE RISKOF THE RISK
MICHAEL COOKMICHAEL COOK
It never took long in the exam room and no
physical exam was done. Started adding
prescriptions to what I wanted. Overdosed 3
times in 2 days, the last time
in the restroom at AAA.
MICHAEL COOKMICHAEL COOK
Went to clinic on April 25, 2008.
Patient’s screen was positive
for opiates. Doctor said he’d taken
6 Opana yesterday.
MATTHEW BRIONESMATTHEW BRIONES
NAYTHAN KENNEYNAYTHAN KENNEY
ERIN WHITNEY:
•DOCTOR’S RECEPTION AREA LOOKED
LIKE A PAROLE OFFICE
• PEOPLE IN THERE HAD LOTS OF
TATTOOS
• DRUG DEALING AND PEOPLE
EXCHANGING NUMBERS
• 2 TO 3 PEOPLE IN EACH EXAM ROOM
•SHE RECEIVED PRESCRIPTIONS FROM
THE DEFENDANT WITH NO EXAM, NO X-
RAYS
NAYTHAN KENNEYNAYTHAN KENNEY
4 DAYS
4 DAYS
SEPTEMBER 16, 2008SEPTEMBER 16, 2008
NAYTHAN KENNEYNAYTHAN KENNEY
STRAUSERSTRAUSER
No medical record except date of
visit, blood pressure and pulse or no
examination of the patient while
giving controlled substances is an
Extreme Departure from the standard
of care. It falls outside the scope of
practice.
DECEASED
DECEASED
NAYTHAN KENNEYNAYTHAN KENNEY
ANDERSONANDERSON
CAUSE OF DEATH: OXYCODONECAUSE OF DEATH: OXYCODONE
AND METHADONEAND METHADONE
BOTH AT TOXIC LEVELSBOTH AT TOXIC LEVELS
OXYCODONE IN THE “HIGHER ECHELON” OF TOXICOXYCODONE IN THE “HIGHER ECHELON” OF TOXIC
CREATING A CAPTIVE AUDIENCECREATING A CAPTIVE AUDIENCE
MICHAEL COOK: WITHDRAWAL IS HELL. THE BODY GETS
WEAKER AND THE TOLERANCE GROWS. IT’S AN EQUATION FOR
DISASTER.
JUSTIN SMITH: WOULD WAIT 2-3 HOURS EACH TIME BECAUSE HE
NEEDED TO GET HIS MEDICATION. WHEN YOU ARE ADDICTED,
YOU DON’T REALLY CARE WHAT YOU TAKE OR WHAT YOU DO. IF
IT MAKES YOU NORMAL OR HIGH, THEN IT WORKS. AND THERE IS
A RISK OF DYING ALMOST EVERY DAY.
LANA RAU: FELT LIKE SHE WAS GOING THROUGH WITHDRAWALS
EVERY MORNING AND NEEDED THE MEDICATION JUST TO FEEL
NORMAL.
ALEXANDER HUY: HE WOULD WAIT UP TO 6 HOURS JUST TO GET
HIS PRESCRIPTION.
DR. EZEKIEL FINKDR. EZEKIEL FINK
IMPACT OF NOTIFICATION OF AIMPACT OF NOTIFICATION OF A
PATIENT DEATH ON THEPATIENT DEATH ON THE
PRACTICE OF MEDICINEPRACTICE OF MEDICINE
““I THINK THAT A PATIENT DYING INI THINK THAT A PATIENT DYING IN
ONE’S CARE WOULD HAVE AONE’S CARE WOULD HAVE A
PROFOUND IMPACT AND WOULD MAKEPROFOUND IMPACT AND WOULD MAKE
ME GO BACK AND TRY TO FIGURE OUTME GO BACK AND TRY TO FIGURE OUT
IF THERE WAS SOMETHING THATIF THERE WAS SOMETHING THAT
COULD HAVE BEEN DONE DIFFERENTCOULD HAVE BEEN DONE DIFFERENT
TO PREVENT THAT DEATH.”TO PREVENT THAT DEATH.”
““DIDN’T CREATE AN ISSUE IN THE OFFICE. WASDIDN’T CREATE AN ISSUE IN THE OFFICE. WAS
AN ORDINARY CALL, MOSTLY FYI.”AN ORDINARY CALL, MOSTLY FYI.”
Dr. Gene Tu
GLORIA RODRIGUEZGLORIA RODRIGUEZ
CASH INCREASEDCASH INCREASED
FROM $500-$600 PERFROM $500-$600 PER
DAYDAY
TO $2,000 SOMETIMESTO $2,000 SOMETIMES
$3,000 PER DAY$3,000 PER DAY
““They’re druggies, theyThey’re druggies, they
can wait.”can wait.”
PER ADVANCED CAREPER ADVANCED CARE
AAA TAX RETURNSAAA TAX RETURNS
2007-20102007-2010
+ $5,000,000+ $5,000,000
IN MILLIONS
ADVANCED CARE AAAADVANCED CARE AAA
CASES OF INTERESTCASES OF INTEREST
PEOPLE V. ESTIANDANPEOPLE V. ESTIANDAN PEOPLE V. KAPOOR, STERN & EROSEVICHPEOPLE V. KAPOOR, STERN & EROSEVICH
PEOPLE V. MURRAYPEOPLE V. MURRAY PEOPLE V. TSENGPEOPLE V. TSENG
MURDER
vs
MANSLAUGHTER
PEOPLE V. CONRAD MURRAYPEOPLE V. CONRAD MURRAY
INVOLUNTARY MANSLAUGHTER
CONVICTEDCONVICTED
BY JURYBY JURY
ISSUESISSUES
THE “WEANING” DEFENSE
PATIENT’S VOLUNTARY INTERFERENCE
WITH TREATMENT
PEOPLE V. CARLOS ESTIANDANPEOPLE V. CARLOS ESTIANDAN
13 FELONY COUNTS OF PRESCRIBING
WITHOUT A LEGITIMATE MEDICAL
PURPOSE
1 FELONY COUNT OF PRESCRIBING TO AN ADDICT
CONVICTEDCONVICTED
BY JURY OFBY JURY OF
ALL 14ALL 14
COUNTSCOUNTS
ISSUESISSUES
FORMER ADDICT AND “PATIENT” AS A WITNESS
ENTRAPMENT DEFENSE
LESLIE GREENBERGLESLIE GREENBERG
DEPUTY LEO NOYOLADEPUTY LEO NOYOLA
CONSPIRACYCONSPIRACY
A conspiracy is an agreement entered into between two or more
persons with the specific intent to agree to commit a crime, followed
by an overt act committed in this state by one or more of the parties
for the purpose of accomplishing the object of the agreement.
Conspiracy is a crime.
WHAT IS A CONSPIRACY?WHAT IS A CONSPIRACY?
PEOPLE V. KAPOOR, EROSEVICH AND STERNPEOPLE V. KAPOOR, EROSEVICH AND STERN
ISSUESISSUES
ADDICT VERSUS PAIN MANAGEMENT
CELEBRITY EXCEPTION
INDUSTRY STANDARD TO PROTECT PRIVACY
JURISDICTION
PEOPLEPEOPLE
v.v.
HSIU-YING “LISA”HSIU-YING “LISA”
TSENGTSENG
3 COUNTS OF SECOND DEGREE MURDER3 COUNTS OF SECOND DEGREE MURDER
20 FELONY PRESCRIBING COUNTS20 FELONY PRESCRIBING COUNTS
DR. EZEKIEL FINKDR. EZEKIEL FINK
ON KNOWLEDGE OF ABUSE
“WHEN A PATIENT COMES IN AND TELLS
YOU THAT THEY’RE AN ACTIVE HEROIN
ADDICT, YOU CANNOT TURN AROUND,
HAND THEM A PRESCRIPTION, AND SAY, ‘I
JUST HAD NO CONTROL OF THAT
PRESCRIPTION.’”
“THE PATIENT TOLD YOU THEY DIDN’T HAVE
CONTROL. YOU HAD THE OPPORTUNITY TO
ACTUALLY MAKE A CHANGE AND BRING THEM BACK
FROM THAT CLIFF, BUT YOU PUSHED THEM.”
SEPTEMBERSEPTEMBER
20082008
KENNEYKENNEY NGUYENNGUYEN
MARCHMARCH
20092009
5 ½ MONTHS5 ½ MONTHS 4 WEEKS4 WEEKS
OGLEOGLE
APRILAPRIL
20092009
KATSNELSONKATSNELSON
APRILAPRIL
20092009
8 DAYS8 DAYS
ROVEROROVERO
DECEMBERDECEMBER
20092009
8 MONTHS8 MONTHS
PATTERNPATTERN
APPRECIATION OF THE RISK/CONSCIOUS DISREGARDAPPRECIATION OF THE RISK/CONSCIOUS DISREGARD
ISSUESISSUES
CAUSATION—DOCTOR SHOPPING
MISDIAGNOSIS DUE TO FALSE INFORMATION
PROVIDED BY PATIENT
FEARED CHILLING EFFECT
OUT ON BAILOUT ON BAIL
DR. THOMAS LINDR. THOMAS LIN
$450,000$450,000
$1,000,000$1,000,000 PHARMACY AUDITPHARMACY AUDIT
HEALTH & SAFETYHEALTH & SAFETY
CODECODE
1115511155
OUT ON BAILOUT ON BAIL
$120,000$120,000
DR. GERARD GORYLDR. GERARD GORYL
DR. GERARD GORYLDR. GERARD GORYL
$1,000,000$1,000,000
OUT ON BAILOUT ON BAIL
OUT ON BAILOUT ON BAIL
DR. GERARD GORYLDR. GERARD GORYL
$2,000,000$2,000,000
CONCLUDING CONSIDERATIONS FOR FILINGCONCLUDING CONSIDERATIONS FOR FILING
SPECIFIC CRIMINAL INTENT
STRENGTH OF EVIDENCE
NUMBER OF VICTIMS
RESOURCES NEEDED TO PROSECUTE
PRIOR CRIMINAL BEHAVIOR
POTENTIAL DEFENSES
 Administrative discipline
 Closure
 Public letter of reprimand
 Cite and fine
 Medical education courses
 Probation
 Revocation
 Criminal discipline
 Probation
 Jail / Prison time
 Fines
Administrative vs. Criminal OutcomesAdministrative vs. Criminal Outcomes
DDA John Niedermann
jniedermann@da.lacounty.gov
(213) 257-2126

More Related Content

What's hot

Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
OPUNITE
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willis
OPUNITE
 
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdevaRx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
OPUNITE
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
OPUNITE
 
Rx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manloveRx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manlove
OPUNITE
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
OPUNITE
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
OPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_group
OPUNITE
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3green
OPUNITE
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3green
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
OPUNITE
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
OPUNITE
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
OPUNITE
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
OPUNITE
 

What's hot (20)

Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willis
 
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdevaRx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
 
Rx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manloveRx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manlove
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_group
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3green
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3green
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
 

Similar to Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill mills

Sexual assault victims
Sexual assault victimsSexual assault victims
Sexual assault victims
Other Mother
 
Medical Legal Aspects and Concerns of the Mid-Level Pratcioner
Medical Legal Aspects and Concerns of the Mid-Level PratcionerMedical Legal Aspects and Concerns of the Mid-Level Pratcioner
Medical Legal Aspects and Concerns of the Mid-Level Pratcioner
Bernard Racey
 
Improving the Safety of Your Healthcare
Improving the Safety of Your HealthcareImproving the Safety of Your Healthcare
Improving the Safety of Your Healthcare
Noel Eldridge
 
Evidence-Based Medicine Overview
Evidence-Based Medicine OverviewEvidence-Based Medicine Overview
Evidence-Based Medicine Overview
Dr. Faisal Al Haddad
 
HIT1443 LEIHP4e Ch13
HIT1443 LEIHP4e Ch13HIT1443 LEIHP4e Ch13
HIT1443 LEIHP4e Ch13
JLynn Jen Smith
 
Ea 6 fingerson gay
Ea 6 fingerson gayEa 6 fingerson gay
Ea 6 fingerson gay
OPUNITE
 
Types of marijuana dtc ads 3.6.18
Types of marijuana dtc ads 3.6.18Types of marijuana dtc ads 3.6.18
Types of marijuana dtc ads 3.6.18
Darshan Kulkarni
 
Denial in cancer patients by Raquel Rodriguez Quintana
Denial in cancer patients by Raquel Rodriguez Quintana Denial in cancer patients by Raquel Rodriguez Quintana
Denial in cancer patients by Raquel Rodriguez Quintana
Jonathan McFarland
 
My Health Journal Eng
My Health Journal  EngMy Health Journal  Eng
My Health Journal Eng
Miki Alexander
 
CDC Webinar: Foodborne illness Outbreaks and Law with Attorney Bill Marler
CDC Webinar:  Foodborne illness Outbreaks and Law with Attorney Bill MarlerCDC Webinar:  Foodborne illness Outbreaks and Law with Attorney Bill Marler
CDC Webinar: Foodborne illness Outbreaks and Law with Attorney Bill Marler
Bill Marler
 
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
e-Patient Dave deBronkart
 
Foodborne Illness Litigation: The Courtroom and the Science with Bill Marler
Foodborne Illness Litigation:  The Courtroom and the Science with Bill MarlerFoodborne Illness Litigation:  The Courtroom and the Science with Bill Marler
Foodborne Illness Litigation: The Courtroom and the Science with Bill Marler
Bill Marler
 
INFORMED CONSENT- 2023-.ppt
INFORMED CONSENT-    2023-.pptINFORMED CONSENT-    2023-.ppt
INFORMED CONSENT- 2023-.ppt
AbdulazizAlkaabba
 
2020 Maryland Law School
2020 Maryland Law School2020 Maryland Law School
2020 Maryland Law School
Bill Marler
 
Patient confidentiality k. creel
Patient confidentiality k. creelPatient confidentiality k. creel
Patient confidentiality k. creel
garnetbaby83
 
Impasse in a detention unit
Impasse in a detention unitImpasse in a detention unit
Impasse in a detention unit
joannakato
 
Rape victim examination . Dr. Sharda Jain Lifecare Centre
Rape victim examination . Dr. Sharda Jain Lifecare CentreRape victim examination . Dr. Sharda Jain Lifecare Centre
Rape victim examination . Dr. Sharda Jain Lifecare Centre
Lifecare Centre
 
Lesson 12
Lesson 12Lesson 12
Lesson 12
Imran Khan
 
Top 10 Question from Ch 6 of Kotler's Marketing Management Book
Top 10 Question from Ch 6 of Kotler's Marketing Management BookTop 10 Question from Ch 6 of Kotler's Marketing Management Book
Top 10 Question from Ch 6 of Kotler's Marketing Management Book
zennia
 
Health & wealth agenda of the provincial federation of ABCs
Health & wealth agenda of the provincial federation of ABCsHealth & wealth agenda of the provincial federation of ABCs
Health & wealth agenda of the provincial federation of ABCs
Arnulfo Laniba
 

Similar to Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill mills (20)

Sexual assault victims
Sexual assault victimsSexual assault victims
Sexual assault victims
 
Medical Legal Aspects and Concerns of the Mid-Level Pratcioner
Medical Legal Aspects and Concerns of the Mid-Level PratcionerMedical Legal Aspects and Concerns of the Mid-Level Pratcioner
Medical Legal Aspects and Concerns of the Mid-Level Pratcioner
 
Improving the Safety of Your Healthcare
Improving the Safety of Your HealthcareImproving the Safety of Your Healthcare
Improving the Safety of Your Healthcare
 
Evidence-Based Medicine Overview
Evidence-Based Medicine OverviewEvidence-Based Medicine Overview
Evidence-Based Medicine Overview
 
HIT1443 LEIHP4e Ch13
HIT1443 LEIHP4e Ch13HIT1443 LEIHP4e Ch13
HIT1443 LEIHP4e Ch13
 
Ea 6 fingerson gay
Ea 6 fingerson gayEa 6 fingerson gay
Ea 6 fingerson gay
 
Types of marijuana dtc ads 3.6.18
Types of marijuana dtc ads 3.6.18Types of marijuana dtc ads 3.6.18
Types of marijuana dtc ads 3.6.18
 
Denial in cancer patients by Raquel Rodriguez Quintana
Denial in cancer patients by Raquel Rodriguez Quintana Denial in cancer patients by Raquel Rodriguez Quintana
Denial in cancer patients by Raquel Rodriguez Quintana
 
My Health Journal Eng
My Health Journal  EngMy Health Journal  Eng
My Health Journal Eng
 
CDC Webinar: Foodborne illness Outbreaks and Law with Attorney Bill Marler
CDC Webinar:  Foodborne illness Outbreaks and Law with Attorney Bill MarlerCDC Webinar:  Foodborne illness Outbreaks and Law with Attorney Bill Marler
CDC Webinar: Foodborne illness Outbreaks and Law with Attorney Bill Marler
 
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
National Board of Medical Examiners 100th Annual Meeting (plenary), 2014
 
Foodborne Illness Litigation: The Courtroom and the Science with Bill Marler
Foodborne Illness Litigation:  The Courtroom and the Science with Bill MarlerFoodborne Illness Litigation:  The Courtroom and the Science with Bill Marler
Foodborne Illness Litigation: The Courtroom and the Science with Bill Marler
 
INFORMED CONSENT- 2023-.ppt
INFORMED CONSENT-    2023-.pptINFORMED CONSENT-    2023-.ppt
INFORMED CONSENT- 2023-.ppt
 
2020 Maryland Law School
2020 Maryland Law School2020 Maryland Law School
2020 Maryland Law School
 
Patient confidentiality k. creel
Patient confidentiality k. creelPatient confidentiality k. creel
Patient confidentiality k. creel
 
Impasse in a detention unit
Impasse in a detention unitImpasse in a detention unit
Impasse in a detention unit
 
Rape victim examination . Dr. Sharda Jain Lifecare Centre
Rape victim examination . Dr. Sharda Jain Lifecare CentreRape victim examination . Dr. Sharda Jain Lifecare Centre
Rape victim examination . Dr. Sharda Jain Lifecare Centre
 
Lesson 12
Lesson 12Lesson 12
Lesson 12
 
Top 10 Question from Ch 6 of Kotler's Marketing Management Book
Top 10 Question from Ch 6 of Kotler's Marketing Management BookTop 10 Question from Ch 6 of Kotler's Marketing Management Book
Top 10 Question from Ch 6 of Kotler's Marketing Management Book
 
Health & wealth agenda of the provincial federation of ABCs
Health & wealth agenda of the provincial federation of ABCsHealth & wealth agenda of the provincial federation of ABCs
Health & wealth agenda of the provincial federation of ABCs
 

More from OPUNITE

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
OPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
OPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
OPUNITE
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
OPUNITE
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
OPUNITE
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
OPUNITE
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
OPUNITE
 

More from OPUNITE (18)

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 

Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill mills

  • 1. Investigating and Prosecuting Pill Mills Presenters: •Jennifer Doll, Special Agent, California Department of Justice •John Niedermann, JD, Deputy District Attorney, Los Angeles County District Attorney’s Office Pre-Summit Workshop Moderator: Karen L. Kelly, District Director, Congressman Harold “Hal” Rogers (KY-5th District), and Member, Rx and Heroin Summit National Advisory Board
  • 2. Disclosures Jennifer Doll; John Niedermann, JD; and Karen L. Kelly have disclosed no relevant, real, or apparent personal or professional financial relationships with proprietary entities that produce healthcare goods and services.
  • 3. Disclosures • All planners/managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. • The following planners/managers have the following to disclose: – John J. Dreyzehner, MD, MPH, FACOEM – Ownership interest: Starfish Health (spouse) – Robert DuPont – Employment: Bensinger, DuPont & Associates-Prescription Drug Research Center
  • 4. Learning Objectives 1. Identify challenges and strategies related to investigating a provider Rx drug case. 2. Distinguish the possible charges that could be filed. 3. Explain how to prepare for and prosecute a criminal trial against a medical professional.
  • 5. PROSECUTING A PRESCRIPTION DRUG CASE: FROM COMPLAINT TO CONVICTION
  • 6. --How investigations are initiated -Constructing an investigation plan -Identifying Drugs -Conducting the investigation -Collecting evidence -Putting it all together -Prosecution and legal issues Course Overview:Course Overview:
  • 7. PEOPLE V. TSENGPEOPLE V. TSENG (LESS THAN 3 YEARS)(LESS THAN 3 YEARS) PC 187 PC 187 PC 187 PC 187 PC 187 PC 187
  • 8.
  • 9. CONSUMER COMPLAINTCONSUMER COMPLAINT -Patient -Family member -Another physician -Pharmacist INITIATION OFINITIATION OF INVESTIGATIONINVESTIGATION
  • 10. SPECIAL AGENT ROBERT HARKINS BEGAN INVESTIGATION IN SEPTEMBER OFBEGAN INVESTIGATION IN SEPTEMBER OF 2008:2008: TIPPED OFF BY LOCAL PHARMACISTSTIPPED OFF BY LOCAL PHARMACISTS CONDUCTED SURVEILLANCE ON THE CLINICCONDUCTED SURVEILLANCE ON THE CLINIC REVEALED LINES OF YOUNG PEOPLEREVEALED LINES OF YOUNG PEOPLE SET UP A SERIES OF UNDERCOVERSET UP A SERIES OF UNDERCOVER OPERATIONSOPERATIONS
  • 11. INITIATION OFINITIATION OF INVESTIGATIONINVESTIGATION DEATH OF A PATIENTDEATH OF A PATIENT --Report from a coroner (802.5)Report from a coroner (802.5) -Family member reports death-Family member reports death -Law enforcement-Law enforcement
  • 12. RYAN LATHAMRYAN LATHAM KELLY RALPHKELLY RALPH:: Had back pain with unknown source but appearedHad back pain with unknown source but appeared to be a sports injury.to be a sports injury. Thought 5 hydrocodone per day was safe.Thought 5 hydrocodone per day was safe. DECEASED DECEASED
  • 14. CRIMINAL VERSUS ADMINSTRATIVE ACTIONSCRIMINAL VERSUS ADMINSTRATIVE ACTIONS Over Prescribing Fraudulent Prescribing Money Laundering / Structuring Tax Fraud Insurance Fraud Prescribing Without a Legitimate Medical Purpose Prescribing to Addicts Homicide Sales/Distribution of Controlled Substances Unlicensed Practice of Medicine
  • 15.
  • 16. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Pros and Cons of Requesting Medical Records via Written request, SDT or Search Warrant
  • 18. SOME PATIENTS HAD BLANK RECORDS IN 2010 THEN HAD COMPLETED RECORDS IN 2012STEVEN OGLESTEVEN OGLE 2010 2012
  • 20. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES IMPORTANTIMPORTANT to obtain original prescriptions early in an investigation to avoid the destruction of the prescriptions and loss of evidence.
  • 21. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES A pharmacist should act as a second screener and is obligated to verify prescriptions in which the legitimacy is questioned. A pharmacist has obligations to go over proper usage of medications in the form of “patient consultations.”
  • 22. PHARMACISTSPHARMACISTS ALFONSO VERCUEIL ANGELA LI LYDIA BRAY KIMBERLY QUACH • YOUNG WHITE MALESYOUNG WHITE MALES • PAYING LARGE AMOUNTS OF CASHPAYING LARGE AMOUNTS OF CASH • ASKING FOR BRAND NAMESASKING FOR BRAND NAMES • APPEARING HEALTHYAPPEARING HEALTHY • REQUESTING UNUSUAL COMBINATIONS OF DRUGSREQUESTING UNUSUAL COMBINATIONS OF DRUGS • SOME APPEARED UNDER THE INFLUENCESOME APPEARED UNDER THE INFLUENCE • SOME APPEARED ANXIOUS OR AGITATEDSOME APPEARED ANXIOUS OR AGITATED ANGELA LIANGELA LI: THE NUMBER OF PRESCRIPTIONS DID NOT DROP: THE NUMBER OF PRESCRIPTIONS DID NOT DROP EVEN AS SHE WAS REFUSING THEMEVEN AS SHE WAS REFUSING THEM LYDIA BRAYLYDIA BRAY: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES AND STRENGTH LIKE THIS AND HASN’T SINCEAND STRENGTH LIKE THIS AND HASN’T SINCE
  • 24. TOXICOLOGY REPORTSTOXICOLOGY REPORTS INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
  • 25. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Toxicology results are often provided with an autopsy report. Typically, a 1 page summary report is provided with the end results of the tests. Be cautious of who signs the toxicology report, as MULTIPLE toxicologists most likely ran tests and may not have signed the report. TOXICOLOGY
  • 26. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Find out the lab’s retention policies and request that the samples for your case be held longer if necessary. Get information of chain of custody. Whose hands touched the vial?? TOXICOLOGY
  • 27. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Understanding the results… Positive / negative versus quantitative Contributing factor of death versus substantial factor Therapeutic versus non-therapeutic TOXICOLOGY
  • 28. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Metabolites- what are the metabolites of certain prescription drugs Metabolism – half life of a drug TOXICOLOGY
  • 29. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Dealing with multiple contributing factors from multiple sources TOXICOLOGY
  • 30. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Witnesses How do I identify witnesses? PDMP reports Surveillance Interviews Pharmacy records Complainant
  • 31. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Witnesses: The Interview How did the patient hear about the subject? Did the patient have a legitimate medical condition? How far did the patient travel to the clinic? How did they pay? Cash? Insurance? How long did they wait to see the subject versus length of exam? Did the subject recommend a specific pharmacy? Did the patient reveal a history of addiction to the subject? When? Show the patient a 6-pack and ask that they identify the subject Did they consume the pills? Sell?
  • 32. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES Be sensitive to their needs / fears / hesitations Don’t judge their addiction or behaviors to obtain medication Talk to your prosecutor about witness concerns and discuss immunity (case by case basis) Witnesses
  • 33.
  • 34. “Holy TrinityHoly Trinity” – combination of three drugs (Soma, Xanax, Vicodin) which create a euphoria like heroin IDENTIFYING DRUGSIDENTIFYING DRUGS
  • 35. Addiction CertificateAddiction Certificate Methadone prescribed for addiction requires a special certificate issued through the DEA (Methadone prescribed for pain does not require this certificate, however the use of the medication must be documented in the chart) IDENTIFYING DRUGSIDENTIFYING DRUGS
  • 36. IDENTIFYING DRUGSIDENTIFYING DRUGS Identify Drugs in your Investigation Report Include a brief summary identifying drugs in your case Include brand name, generic name and schedule Note for what condition drug is used Cite current schedule at the time the drug was dispensed or administered
  • 37.
  • 38. THE UNDERCOVER OPERATIONS SPECIAL AGENT STEPHANIE MORELANDSPECIAL AGENT STEPHANIE MORELAND APRIL 25, 2008APRIL 25, 2008 • TOLD DEFENDANT SHE NEEDED SOMETHING FOR CRAMPS AND A HEADACHE • TOLD THE DEFENDANT SHE WAS COMING FROM OCEANSIDE • NO PHYSICAL EXAM WAS GIVEN • DEFENDANT SAID SHE WOULD PRESCRIBE VICODIN TO TAKE THE EDGES OFF UNCHARGEDUNCHARGED
  • 39. Pain vs No pain Recording Devices (should you have them? Where should you put them?) How many buys are necessary? Establishing a rapport the doctor Testifying after your U/C Entrapment / Red flags Undercover Investigations: IssuesUndercover Investigations: Issues CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
  • 40. CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION THE “MEATY” STUFFTHE “MEATY” STUFF
  • 41. CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION SEARCH WARRANTSSEARCH WARRANTS What are you trying to obtain? What probable cause is needed to obtain those items? Do you have probable cause? Can you ever have too much information in a SW? Tools to assist with SW writing PREPARING SEARCH WARRANTSPREPARING SEARCH WARRANTS
  • 42. SEARCH WARRANTSEARCH WARRANT LOCATIONSLOCATIONS HOMEHOME BUSINESSBUSINESS STORAGESTORAGE CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION SEARCH WARRANTSSEARCH WARRANTS
  • 43. CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION SEARCH WARRANTSSEARCH WARRANTS Getting your warrant signed - Finding a judge - Educating your judge - Know your case (the judge will probably ask questions)
  • 44.
  • 46. COLLECTING EVIDENCECOLLECTING EVIDENCE EXECUTING A WARRANT Securing the evidence: If computer equipment is expected to be taken, consider staff / subject destroying evidence upon entry. Do you have a technical team that can safely remove digital data without compromising the data?
  • 47. COMPUTER RECORDSCOMPUTER RECORDS COLLECTING EVIDENCECOLLECTING EVIDENCE Specific language in SW to search computer files Agency assist in collection of files Agency assist in analyzing data- DOJ, FBI, locals, etc. Consider turn around time for data to be recovered Search warrant return – language for additional time for digital data Consider the cloud
  • 48. LUIS SALAZARLUIS SALAZAR NO DAMAGE TONO DAMAGE TO THE COMPUTERSTHE COMPUTERS
  • 49. KNOW YOUR TARGETSKNOW YOUR TARGETS
  • 50. WHO WAS THEREWHO WAS THERE PHYSICIANPHYSICIAN WAS THE DOCTOR WITH AWAS THE DOCTOR WITH A PATIENTPATIENT WAS THE DOCTORWAS THE DOCTOR COOPERATIVECOOPERATIVE DID THE DOCTOR SUBMIT TODID THE DOCTOR SUBMIT TO BE INTERVIEWEDBE INTERVIEWED DOES THE DOCTOR HAVE ADOES THE DOCTOR HAVE A PRIOR RECORDPRIOR RECORD WHAT WAS THEIR CHIEF AREAWHAT WAS THEIR CHIEF AREA OF PRACTICEOF PRACTICE WHAT BOARDWHAT BOARD CERTIFICATIONS DO THEYCERTIFICATIONS DO THEY HAVEHAVE
  • 51. WHO WAS THEREWHO WAS THERE PHYSICIAN’S ASSISTANTPHYSICIAN’S ASSISTANT WAS HE SEEING PATIENTSWAS HE SEEING PATIENTS WHAT DUTIES WEREWHAT DUTIES WERE DELEGATED TO HIMDELEGATED TO HIM IS THERE A DELEGATION OFIS THERE A DELEGATION OF SERVICES AGREEMENTSERVICES AGREEMENT WHAT IS HIS SKILL SETWHAT IS HIS SKILL SET WHAT HOURS DOES HE WORK INWHAT HOURS DOES HE WORK IN RELATION TO THE DOCTORRELATION TO THE DOCTOR
  • 52. WHO WAS THEREWHO WAS THERE MEDICAL ASSISTANTMEDICAL ASSISTANT RECEPTIONISTRECEPTIONIST WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES DO THEY HAVE MEDICALDO THEY HAVE MEDICAL TRAININGTRAINING HOW DO THEY INTERACT WITHHOW DO THEY INTERACT WITH PATIENTSPATIENTS WHO DOES BOOKKEEPINGWHO DOES BOOKKEEPING HOW ARE RECORDS KEPTHOW ARE RECORDS KEPT HOW DOES THE FRONT OF THEHOW DOES THE FRONT OF THE OFFICE RUNOFFICE RUN WHAT TYPES OF PATIENTS AREWHAT TYPES OF PATIENTS ARE SEENSEEN
  • 53. WHO WAS THEREWHO WAS THERE RUNNERSRUNNERS CAPPERSCAPPERS WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES HOW WERE THEY TRAINEDHOW WERE THEY TRAINED HOW ARE THEY PAIDHOW ARE THEY PAID WHAT IS THEIR RELATIONSHIP TOWHAT IS THEIR RELATIONSHIP TO THE DOCTORTHE DOCTOR
  • 54. PHYSICIAN’S OFFICE –Photos, Photos, Photos COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 58. TODAYTODAY THE FUTURETHE FUTURE FINANCIAL RECORDSFINANCIAL RECORDS COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 59. BANK RECORDSBANK RECORDS COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 60. COLLECTING EVIDENCECOLLECTING EVIDENCE ITEMS ESTABLISHING DOMINION AND CONTROL OF PREMISESITEMS ESTABLISHING DOMINION AND CONTROL OF PREMISES (utility bills, leases, etc.)
  • 61. SPECIFIC MEDICALSPECIFIC MEDICAL RECORDS LISTED BYRECORDS LISTED BY PATIENTPATIENT Include a description of what a medical record is. (i.e. physical / electronic charts, x-rays, phone messages, insurance billing, labs, prescriptions, etc) COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 62.
  • 63. COLLECTING EVIDENCECOLLECTING EVIDENCE MEDICAL CHARTMEDICAL CHART BILLING STATEMENTBILLING STATEMENT PHENTERMINEPHENTERMINE
  • 64. COLLECTING EVIDENCECOLLECTING EVIDENCE CELL PHONE INFORMATION VIA SEARCH WARRANTCELL PHONE INFORMATION VIA SEARCH WARRANT
  • 65.
  • 66. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED IN A DRAWER:IN A DRAWER: WAS IT CLOSED (KNOWLEDGE)WAS IT CLOSED (KNOWLEDGE) WAS IT LOCKED (ACCESS)WAS IT LOCKED (ACCESS) IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL)IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL) WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)
  • 67. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED ON A SHELF:ON A SHELF: HOW WERE THE RECORDS ARRANGED (STANDARD OFHOW WERE THE RECORDS ARRANGED (STANDARD OF CARE)CARE) WHO WAS RESPONSIBLE FOR MAKING NOTATIONSWHO WAS RESPONSIBLE FOR MAKING NOTATIONS (KNOWLEDGE)(KNOWLEDGE) WHO HAD ACCESS TO THE RECORDS (DELEGATION)WHO HAD ACCESS TO THE RECORDS (DELEGATION)
  • 68. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED IN A BATHROOM:IN A BATHROOM: WHO HAD ACCESS (STANDARD OF CARE)WHO HAD ACCESS (STANDARD OF CARE) WERE CONTROLLED SUBSTANCES MIXED WITH NON-WERE CONTROLLED SUBSTANCES MIXED WITH NON- CONTROLLED SUBSTANCES (NEGLIGENCE)CONTROLLED SUBSTANCES (NEGLIGENCE)
  • 69. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED IN A PILL ROOM:IN A PILL ROOM: WERE THERE LOOSE PILLS (NEGLIGENCE)WERE THERE LOOSE PILLS (NEGLIGENCE) WERE THERE NON-MEDICAL ITEMS LOCATEDWERE THERE NON-MEDICAL ITEMS LOCATED (STANDARD OF CARE)(STANDARD OF CARE) WHO HAD ACCESS TO THE ROOM (CONTROL)WHO HAD ACCESS TO THE ROOM (CONTROL)
  • 70. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED IN A CAR:IN A CAR: WERE ITEMS LOCKED AND SECURED (STANDARD OFWERE ITEMS LOCKED AND SECURED (STANDARD OF CARE)CARE) WERE ITEMS LABELED OR SCRIPTS FILLED OUTWERE ITEMS LABELED OR SCRIPTS FILLED OUT (MOTIVE)(MOTIVE)
  • 73. APPLICATIONS FOR CERTIFICATIONAPPLICATIONS FOR CERTIFICATION COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 74. DIVERTED MEDICATION BOTTLESDIVERTED MEDICATION BOTTLES COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 75. PHARMACIST STEVE MAZLIN INTERVIEWS WITH PHARMICISTS:INTERVIEWS WITH PHARMICISTS: WARNINGSWARNINGS Chloral Hydrate is a veryChloral Hydrate is a very powerful respiratorypowerful respiratory suppressant. You don’t wantsuppressant. You don’t want to end up on the cover of theto end up on the cover of the “National Inquirer.”“National Inquirer.” I had to correct Dr. Eroshevich onI had to correct Dr. Eroshevich on the dosing on her prescription.the dosing on her prescription. COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 76. HARD COPY PRESCRIPTIONSHARD COPY PRESCRIPTIONS COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 77. ANNA NICOLE SMITH’S MEDICAL HISTORYANNA NICOLE SMITH’S MEDICAL HISTORY HOWARD K. STERN’S MEDICAL HISTORYHOWARD K. STERN’S MEDICAL HISTORY INTAKE PATIENT PROFILESINTAKE PATIENT PROFILES COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 80. SURVEILLANCE VIDEO OR STILLSSURVEILLANCE VIDEO OR STILLS COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 81. PERSONAL PHOTOGRAPHS: CORROBORATIONPERSONAL PHOTOGRAPHS: CORROBORATION MAKE: CANON MODEL: CANON EOS DIGITALREBEL XT DATE: 2006:09:21 TIME: 02:13:36 COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 82. 12/19/0612/19/06 EXTERNALEXTERNAL HARD DRIVEHARD DRIVE PERSONAL PHOTOGRAPHS: MOTIVEPERSONAL PHOTOGRAPHS: MOTIVE COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 83. LOCATIONS WHERE PATIENTS LIVELOCATIONS WHERE PATIENTS LIVE DOCTOR’S OFFICE PATIENT RESIDENCES 30 MILES COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 84. LANA RAULANA RAU 20072007 20082008 20092009 PATTERNS OF PRESCRIBINGPATTERNS OF PRESCRIBING COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 85. Coroner’s Reports Witness / family statements made to coroner investigators Admissions of doctor to coroner staff / investigators Coroner investigator notes (not included in autopsy report) Photos: COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 86. CORONER’S RECORDS AND NOTES COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 89. COLLECTING EVIDENCECOLLECTING EVIDENCE EXPERT OPINIONS Once evidence is obtained, determine if an expert opinion is necessary. Make sure the expert has the entire picture of the case, not just a snap shot (for example, just having an expert review a PDMP report)
  • 90. COLLECTING EVIDENCECOLLECTING EVIDENCE EXPERT OPINIONS Expert opinions are critical to most over-prescribing cases. Consider the strength of your case depending on your expert’s findings: no departure, simple departure, extremeno departure, simple departure, extreme departure and lack of knowledgedeparture and lack of knowledge
  • 91. DR. WALTER STRAUSERDR. WALTER STRAUSER THE STANDARD OF CARETHE STANDARD OF CARE “THE LEVEL OF SKILL, KNOWLEDGE AND CARE IN DIAGNOSING AND TREATING THAT A REASONABLY PRUDENT PHYSICIAN WOULD EXERCISE IN SIMILAR CIRCUMSTANCES.” THE SAME STANDARD OF CARE APPLIES TO ALL PHYSICIANS AN EXTREME DEPARTURE FROM THE STANDARD OF CARE: GROSS NEGLIGENCE AND LACK OF SCANT CARE
  • 92. No inquiry into who the other doctors were and why so much medication at his age MEDICAL OPINIONSMEDICAL OPINIONS EXTREME DEPARTUREEXTREME DEPARTURE COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 93. TOXICOLOGISTTOXICOLOGIST TOXICOLOGIST TOXICOLOGIST “The Opana was 3-4 X therapeutic levels and the main contributor. Xanax was at therapeutic levels. Opana was the substantial cause of death.” COLLECTING EVIDENCECOLLECTING EVIDENCE
  • 94.
  • 95.
  • 96.
  • 97. FELONY MURDERFELONY MURDER +TheThe unlawful killingunlawful killing of a human being,of a human being, +WhetherWhether intentionalintentional,, unintentionalunintentional, or, or accidentalaccidental,, +WhichWhich occurs duringoccurs during the commissionthe commission or attempted commission of a felony,or attempted commission of a felony, +When the perpetrator had theWhen the perpetrator had the specificspecific intentintent toto commit that specified felonycommit that specified felony = MURDER
  • 98. FELONY MURDERFELONY MURDER +TheThe unlawful killingunlawful killing of a human being,of a human being, +WhetherWhether intentionalintentional,, unintentionalunintentional, or, or accidentalaccidental,, +WhichWhich occurs duringoccurs during the commissionthe commission or attempted commission of felony,or attempted commission of felony, +When the perpetrator had theWhen the perpetrator had the specificspecific intentintent toto commit that specified felonycommit that specified felony = MURDER CALIFORNIACALIFORNIA OVER-PRESCRIBING STATUTESOVER-PRESCRIBING STATUTES
  • 101. SECOND DEGREE MURDER DANGEROUS TO LIFE 1. The killing resulted from an intentional act, 2. The natural consequences of the act are dangerous to human life, and 3. The act was deliberately performed with knowledge of the danger to, and with conscious disregard for, human life. • When the killing is the direct result of such an act, it isWhen the killing is the direct result of such an act, it is not necessary to prove that the defendant intended thatnot necessary to prove that the defendant intended that the act would result in the death of a human being.the act would result in the death of a human being.
  • 103.
  • 105. MICHAEL COOKMICHAEL COOK It never took long in the exam room and no physical exam was done. Started adding prescriptions to what I wanted. Overdosed 3 times in 2 days, the last time in the restroom at AAA.
  • 106. MICHAEL COOKMICHAEL COOK Went to clinic on April 25, 2008. Patient’s screen was positive for opiates. Doctor said he’d taken 6 Opana yesterday. MATTHEW BRIONESMATTHEW BRIONES
  • 107. NAYTHAN KENNEYNAYTHAN KENNEY ERIN WHITNEY: •DOCTOR’S RECEPTION AREA LOOKED LIKE A PAROLE OFFICE • PEOPLE IN THERE HAD LOTS OF TATTOOS • DRUG DEALING AND PEOPLE EXCHANGING NUMBERS • 2 TO 3 PEOPLE IN EACH EXAM ROOM •SHE RECEIVED PRESCRIPTIONS FROM THE DEFENDANT WITH NO EXAM, NO X- RAYS
  • 108. NAYTHAN KENNEYNAYTHAN KENNEY 4 DAYS 4 DAYS SEPTEMBER 16, 2008SEPTEMBER 16, 2008
  • 109. NAYTHAN KENNEYNAYTHAN KENNEY STRAUSERSTRAUSER No medical record except date of visit, blood pressure and pulse or no examination of the patient while giving controlled substances is an Extreme Departure from the standard of care. It falls outside the scope of practice.
  • 110. DECEASED DECEASED NAYTHAN KENNEYNAYTHAN KENNEY ANDERSONANDERSON CAUSE OF DEATH: OXYCODONECAUSE OF DEATH: OXYCODONE AND METHADONEAND METHADONE BOTH AT TOXIC LEVELSBOTH AT TOXIC LEVELS OXYCODONE IN THE “HIGHER ECHELON” OF TOXICOXYCODONE IN THE “HIGHER ECHELON” OF TOXIC
  • 111.
  • 112. CREATING A CAPTIVE AUDIENCECREATING A CAPTIVE AUDIENCE MICHAEL COOK: WITHDRAWAL IS HELL. THE BODY GETS WEAKER AND THE TOLERANCE GROWS. IT’S AN EQUATION FOR DISASTER. JUSTIN SMITH: WOULD WAIT 2-3 HOURS EACH TIME BECAUSE HE NEEDED TO GET HIS MEDICATION. WHEN YOU ARE ADDICTED, YOU DON’T REALLY CARE WHAT YOU TAKE OR WHAT YOU DO. IF IT MAKES YOU NORMAL OR HIGH, THEN IT WORKS. AND THERE IS A RISK OF DYING ALMOST EVERY DAY. LANA RAU: FELT LIKE SHE WAS GOING THROUGH WITHDRAWALS EVERY MORNING AND NEEDED THE MEDICATION JUST TO FEEL NORMAL. ALEXANDER HUY: HE WOULD WAIT UP TO 6 HOURS JUST TO GET HIS PRESCRIPTION.
  • 113. DR. EZEKIEL FINKDR. EZEKIEL FINK IMPACT OF NOTIFICATION OF AIMPACT OF NOTIFICATION OF A PATIENT DEATH ON THEPATIENT DEATH ON THE PRACTICE OF MEDICINEPRACTICE OF MEDICINE ““I THINK THAT A PATIENT DYING INI THINK THAT A PATIENT DYING IN ONE’S CARE WOULD HAVE AONE’S CARE WOULD HAVE A PROFOUND IMPACT AND WOULD MAKEPROFOUND IMPACT AND WOULD MAKE ME GO BACK AND TRY TO FIGURE OUTME GO BACK AND TRY TO FIGURE OUT IF THERE WAS SOMETHING THATIF THERE WAS SOMETHING THAT COULD HAVE BEEN DONE DIFFERENTCOULD HAVE BEEN DONE DIFFERENT TO PREVENT THAT DEATH.”TO PREVENT THAT DEATH.” ““DIDN’T CREATE AN ISSUE IN THE OFFICE. WASDIDN’T CREATE AN ISSUE IN THE OFFICE. WAS AN ORDINARY CALL, MOSTLY FYI.”AN ORDINARY CALL, MOSTLY FYI.” Dr. Gene Tu
  • 114. GLORIA RODRIGUEZGLORIA RODRIGUEZ CASH INCREASEDCASH INCREASED FROM $500-$600 PERFROM $500-$600 PER DAYDAY TO $2,000 SOMETIMESTO $2,000 SOMETIMES $3,000 PER DAY$3,000 PER DAY ““They’re druggies, theyThey’re druggies, they can wait.”can wait.” PER ADVANCED CAREPER ADVANCED CARE AAA TAX RETURNSAAA TAX RETURNS 2007-20102007-2010 + $5,000,000+ $5,000,000
  • 115. IN MILLIONS ADVANCED CARE AAAADVANCED CARE AAA
  • 116.
  • 117. CASES OF INTERESTCASES OF INTEREST PEOPLE V. ESTIANDANPEOPLE V. ESTIANDAN PEOPLE V. KAPOOR, STERN & EROSEVICHPEOPLE V. KAPOOR, STERN & EROSEVICH PEOPLE V. MURRAYPEOPLE V. MURRAY PEOPLE V. TSENGPEOPLE V. TSENG
  • 119. PEOPLE V. CONRAD MURRAYPEOPLE V. CONRAD MURRAY INVOLUNTARY MANSLAUGHTER CONVICTEDCONVICTED BY JURYBY JURY
  • 120. ISSUESISSUES THE “WEANING” DEFENSE PATIENT’S VOLUNTARY INTERFERENCE WITH TREATMENT
  • 121. PEOPLE V. CARLOS ESTIANDANPEOPLE V. CARLOS ESTIANDAN 13 FELONY COUNTS OF PRESCRIBING WITHOUT A LEGITIMATE MEDICAL PURPOSE 1 FELONY COUNT OF PRESCRIBING TO AN ADDICT CONVICTEDCONVICTED BY JURY OFBY JURY OF ALL 14ALL 14 COUNTSCOUNTS
  • 122. ISSUESISSUES FORMER ADDICT AND “PATIENT” AS A WITNESS ENTRAPMENT DEFENSE LESLIE GREENBERGLESLIE GREENBERG DEPUTY LEO NOYOLADEPUTY LEO NOYOLA
  • 123. CONSPIRACYCONSPIRACY A conspiracy is an agreement entered into between two or more persons with the specific intent to agree to commit a crime, followed by an overt act committed in this state by one or more of the parties for the purpose of accomplishing the object of the agreement. Conspiracy is a crime. WHAT IS A CONSPIRACY?WHAT IS A CONSPIRACY?
  • 124. PEOPLE V. KAPOOR, EROSEVICH AND STERNPEOPLE V. KAPOOR, EROSEVICH AND STERN
  • 125. ISSUESISSUES ADDICT VERSUS PAIN MANAGEMENT CELEBRITY EXCEPTION INDUSTRY STANDARD TO PROTECT PRIVACY JURISDICTION
  • 127. 3 COUNTS OF SECOND DEGREE MURDER3 COUNTS OF SECOND DEGREE MURDER 20 FELONY PRESCRIBING COUNTS20 FELONY PRESCRIBING COUNTS
  • 128. DR. EZEKIEL FINKDR. EZEKIEL FINK ON KNOWLEDGE OF ABUSE “WHEN A PATIENT COMES IN AND TELLS YOU THAT THEY’RE AN ACTIVE HEROIN ADDICT, YOU CANNOT TURN AROUND, HAND THEM A PRESCRIPTION, AND SAY, ‘I JUST HAD NO CONTROL OF THAT PRESCRIPTION.’” “THE PATIENT TOLD YOU THEY DIDN’T HAVE CONTROL. YOU HAD THE OPPORTUNITY TO ACTUALLY MAKE A CHANGE AND BRING THEM BACK FROM THAT CLIFF, BUT YOU PUSHED THEM.”
  • 129. SEPTEMBERSEPTEMBER 20082008 KENNEYKENNEY NGUYENNGUYEN MARCHMARCH 20092009 5 ½ MONTHS5 ½ MONTHS 4 WEEKS4 WEEKS OGLEOGLE APRILAPRIL 20092009 KATSNELSONKATSNELSON APRILAPRIL 20092009 8 DAYS8 DAYS ROVEROROVERO DECEMBERDECEMBER 20092009 8 MONTHS8 MONTHS PATTERNPATTERN APPRECIATION OF THE RISK/CONSCIOUS DISREGARDAPPRECIATION OF THE RISK/CONSCIOUS DISREGARD
  • 130. ISSUESISSUES CAUSATION—DOCTOR SHOPPING MISDIAGNOSIS DUE TO FALSE INFORMATION PROVIDED BY PATIENT
  • 132.
  • 133. OUT ON BAILOUT ON BAIL DR. THOMAS LINDR. THOMAS LIN $450,000$450,000 $1,000,000$1,000,000 PHARMACY AUDITPHARMACY AUDIT HEALTH & SAFETYHEALTH & SAFETY CODECODE 1115511155
  • 134. OUT ON BAILOUT ON BAIL $120,000$120,000 DR. GERARD GORYLDR. GERARD GORYL
  • 135. DR. GERARD GORYLDR. GERARD GORYL $1,000,000$1,000,000 OUT ON BAILOUT ON BAIL
  • 136. OUT ON BAILOUT ON BAIL DR. GERARD GORYLDR. GERARD GORYL $2,000,000$2,000,000
  • 137. CONCLUDING CONSIDERATIONS FOR FILINGCONCLUDING CONSIDERATIONS FOR FILING SPECIFIC CRIMINAL INTENT STRENGTH OF EVIDENCE NUMBER OF VICTIMS RESOURCES NEEDED TO PROSECUTE PRIOR CRIMINAL BEHAVIOR POTENTIAL DEFENSES
  • 138.  Administrative discipline  Closure  Public letter of reprimand  Cite and fine  Medical education courses  Probation  Revocation  Criminal discipline  Probation  Jail / Prison time  Fines Administrative vs. Criminal OutcomesAdministrative vs. Criminal Outcomes